http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Aug 2026 17:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17/26951038.html si-local-file:///var/storage/secattach/20260819/26951038.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17/26951038.html Wed, 19 Aug 2026 17:07:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17/26951038.html si-local-file:///var/storage/secattach/20260819/26951038.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17/26951038.html Wed, 19 Aug 2026 17:07:00 -0400 O.48222974 REVB http://www.streetinsider.com/FDA/Revelation+Biosciences+picks+Avance+Clinical+for+kidney+injury+trial/26947939.html <p>Revelation Biosciences, Inc. (NASDAQ: REVB) has selected Avance Clinical as the contract research organization (CRO) for its Phase 2/3 adaptive-design TITAN study evaluating its drug candidate Gemini in patients with acute kidney injury (AKI), according to a press release.</p> <p>The company said the study is on track to begin later this year. Avance Clinical will be responsible for site identification and management, patient recruitment, safety monitoring, and data management for the trial.</p> <p>"The Company selected Avance Clinical following an extensive evaluation process," said James Rolke, Chief Executive Officer of Revelation. "Working closely with Avance, the Revelation team remains committed to starting this http://www.streetinsider.com/FDA/Revelation+Biosciences+picks+Avance+Clinical+for+kidney+injury+trial/26947939.html Wed, 19 Aug 2026 09:00:42 -0400 O.48222974 REVB http://www.streetinsider.com/FDA/Revelation+Biosciences+picks+Avance+Clinical+for+kidney+injury+trial/26947939.html <p>Revelation Biosciences, Inc. (NASDAQ: REVB) has selected Avance Clinical as the contract research organization (CRO) for its Phase 2/3 adaptive-design TITAN study evaluating its drug candidate Gemini in patients with acute kidney injury (AKI), according to a press release.</p> <p>The company said the study is on track to begin later this year. Avance Clinical will be responsible for site identification and management, patient recruitment, safety monitoring, and data management for the trial.</p> <p>"The Company selected Avance Clinical following an extensive evaluation process," said James Rolke, Chief Executive Officer of Revelation. "Working closely with Avance, the Revelation team remains committed to starting this http://www.streetinsider.com/FDA/Revelation+Biosciences+picks+Avance+Clinical+for+kidney+injury+trial/26947939.html Wed, 19 Aug 2026 09:00:42 -0400 O.48222974 REVB http://www.streetinsider.com/Press+Releases/Revelation+Biosciences+Selects+Avance+Clinical+as+CRO+for+Phase+23+TITAN+Study/26947904.html <p class="bwalignc"> <b><i>– </i></b><i>Study on track to begin later this year <b>–</b></i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.RevBiosciences.com&amp;esheet=54591738&amp;newsitemid=20260819546599&amp;lan=en-US&amp;anchor=Revelation+Biosciences%2C+Inc.&amp;index=1&amp;md5=2279c909556cad95ef5d2bd0e527332f" shape="rect">Revelation Biosciences, Inc.</a> (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI). </p><p> The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the http://www.streetinsider.com/Press+Releases/Revelation+Biosciences+Selects+Avance+Clinical+as+CRO+for+Phase+23+TITAN+Study/26947904.html Wed, 19 Aug 2026 09:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/Press+Releases/Revelation+Biosciences+Selects+Avance+Clinical+as+CRO+for+Phase+23+TITAN+Study/26947904.html <p class="bwalignc"> <b><i>– </i></b><i>Study on track to begin later this year <b>–</b></i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.RevBiosciences.com&amp;esheet=54591738&amp;newsitemid=20260819546599&amp;lan=en-US&amp;anchor=Revelation+Biosciences%2C+Inc.&amp;index=1&amp;md5=2279c909556cad95ef5d2bd0e527332f" shape="rect">Revelation Biosciences, Inc.</a> (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI). </p><p> The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the http://www.streetinsider.com/Press+Releases/Revelation+Biosciences+Selects+Avance+Clinical+as+CRO+for+Phase+23+TITAN+Study/26947904.html Wed, 19 Aug 2026 09:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/Business+Wire/Revelation+Biosciences+Selects+Avance+Clinical+as+CRO+for+Phase+23+TITAN+Study/26947904.html <p class="bwalignc"> <b><i>– </i></b><i>Study on track to begin later this year <b>–</b></i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.RevBiosciences.com&amp;esheet=54591738&amp;newsitemid=20260819546599&amp;lan=en-US&amp;anchor=Revelation+Biosciences%2C+Inc.&amp;index=1&amp;md5=2279c909556cad95ef5d2bd0e527332f" shape="rect">Revelation Biosciences, Inc.</a> (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI). </p><p> The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the http://www.streetinsider.com/Business+Wire/Revelation+Biosciences+Selects+Avance+Clinical+as+CRO+for+Phase+23+TITAN+Study/26947904.html Wed, 19 Aug 2026 09:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/Business+Wire/Revelation+Biosciences+Selects+Avance+Clinical+as+CRO+for+Phase+23+TITAN+Study/26947904.html <p class="bwalignc"> <b><i>– </i></b><i>Study on track to begin later this year <b>–</b></i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.RevBiosciences.com&amp;esheet=54591738&amp;newsitemid=20260819546599&amp;lan=en-US&amp;anchor=Revelation+Biosciences%2C+Inc.&amp;index=1&amp;md5=2279c909556cad95ef5d2bd0e527332f" shape="rect">Revelation Biosciences, Inc.</a> (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI). </p><p> The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the http://www.streetinsider.com/Business+Wire/Revelation+Biosciences+Selects+Avance+Clinical+as+CRO+for+Phase+23+TITAN+Study/26947904.html Wed, 19 Aug 2026 09:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+CARVER+JENNIFER/26945211.html si-local-file:///var/storage/secattach/20260818/26945211.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+CARVER+JENNIFER/26945211.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+CARVER+JENNIFER/26945211.html si-local-file:///var/storage/secattach/20260818/26945211.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+CARVER+JENNIFER/26945211.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+ROPER+JESS/26945212.html si-local-file:///var/storage/secattach/20260818/26945212.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+ROPER+JESS/26945212.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+ROPER+JESS/26945212.html si-local-file:///var/storage/secattach/20260818/26945212.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+ROPER+JESS/26945212.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Rolke+James/26945217.html si-local-file:///var/storage/secattach/20260818/26945217.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Rolke+James/26945217.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Rolke+James/26945217.html si-local-file:///var/storage/secattach/20260818/26945217.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Rolke+James/26945217.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Zygmont+Chester+Stanley+III/26945219.html si-local-file:///var/storage/secattach/20260818/26945219.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Zygmont+Chester+Stanley+III/26945219.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Zygmont+Chester+Stanley+III/26945219.html si-local-file:///var/storage/secattach/20260818/26945219.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Zygmont+Chester+Stanley+III/26945219.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Chawla+Lakhmir+S/26945224.html si-local-file:///var/storage/secattach/20260818/26945224.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Chawla+Lakhmir+S/26945224.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Chawla+Lakhmir+S/26945224.html si-local-file:///var/storage/secattach/20260818/26945224.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+17++Filed+by%3A+Chawla+Lakhmir+S/26945224.html Tue, 18 Aug 2026 17:00:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++REVELATION+BIOSCIENCES%2C++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926367.html si-local-file:///var/storage/secattach/20260814/26926367.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++REVELATION+BIOSCIENCES%2C++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926367.html Fri, 14 Aug 2026 10:24:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++REVELATION+BIOSCIENCES%2C++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926367.html si-local-file:///var/storage/secattach/20260814/26926367.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++REVELATION+BIOSCIENCES%2C++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926367.html Fri, 14 Aug 2026 10:24:00 -0400 O.48222974 REVB http://www.streetinsider.com/Earnings/Revelation+Biosciences+%28REVB%29+Misses+Q2+EPS+by+4c/26891385.html <p>Revelation Biosciences (NASDAQ: REVB) reported Q2 EPS of ($0.87), $0.04 worse than the analyst estimate of ($0.83).</p><p>For earnings history and earnings-related data on Revelation Biosciences (REVB) <a href="http://www.streetinsider.com/ec_earnings.php?q=REVB">click here</a>.</p> http://www.streetinsider.com/Earnings/Revelation+Biosciences+%28REVB%29+Misses+Q2+EPS+by+4c/26891385.html Fri, 07 Aug 2026 16:22:14 -0400 REVB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+06/26884434.html si-local-file:///var/storage/secattach/20260806/26884434.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+06/26884434.html Thu, 06 Aug 2026 16:20:00 -0400 O.48222974 REVB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+06/26884434.html si-local-file:///var/storage/secattach/20260806/26884434.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVELATION+BIOSCIENCES%2C+++For%3A+Aug+06/26884434.html Thu, 06 Aug 2026 16:20:00 -0400 O.48222974 REVB http://www.streetinsider.com/Press+Releases/Revelation+Biosciences%2C+Inc.+Announces+Financial+Results+for+the+Three+and+Six+Months+Ended+June+30%2C+2026/26884032.html <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 6, 2026 / </strong><a rel="nofollow" href="https://pr.report/os39">Revelation Biosciences, Inc.</a> (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and six months ended June 30, 2026.</p><p><strong>Corporate Highlights</strong></p><ul style="list-style-type:disc;"><li><p>Announced formation of <a rel="nofollow" href="https://pr.report/os3b">an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial</a> and subsequent <a rel="nofollow" href="https://pr.report/os3c">expansion of the AKI Advisory Board</a></p></li><li><p>Continued progress on Phase 2/3 clinical study start up activities</p></li><li><p>Released results of an http://www.streetinsider.com/Press+Releases/Revelation+Biosciences%2C+Inc.+Announces+Financial+Results+for+the+Three+and+Six+Months+Ended+June+30%2C+2026/26884032.html Thu, 06 Aug 2026 16:15:00 -0400 REVB http://www.streetinsider.com/ACCESS+Newswire/Revelation+Biosciences%2C+Inc.+Announces+Financial+Results+for+the+Three+and+Six+Months+Ended+June+30%2C+2026/26884032.html <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 6, 2026 / </strong><a rel="nofollow" href="https://pr.report/os39">Revelation Biosciences, Inc.</a> (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and six months ended June 30, 2026.</p><p><strong>Corporate Highlights</strong></p><ul style="list-style-type:disc;"><li><p>Announced formation of <a rel="nofollow" href="https://pr.report/os3b">an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial</a> and subsequent <a rel="nofollow" href="https://pr.report/os3c">expansion of the AKI Advisory Board</a></p></li><li><p>Continued progress on Phase 2/3 clinical study start up activities</p></li><li><p>Released results of an http://www.streetinsider.com/ACCESS+Newswire/Revelation+Biosciences%2C+Inc.+Announces+Financial+Results+for+the+Three+and+Six+Months+Ended+June+30%2C+2026/26884032.html Thu, 06 Aug 2026 16:15:00 -0400 REVB